<DOC>
	<DOCNO>NCT02528903</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled , single-ascending dose study healthy volunteer investigate safety , tolerability , pharmacokinetics ( PK ) MHAB5553A .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics MHAB5553A Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Signed informed consent form ( ICF ) Body mass index ( BMI ) 18 32 kg/m2 , inclusive Weight 40100 kg In good health , determine clinically significant finding medical history , 12lead ECG , vital sign Clinical laboratory evaluation within reference range test , unless deem clinically significant investigator sponsor screen Willing abstain use drug abuse enrol study Willing able comply protocolspecified criterion regard contraceptive protection Able comply study protocol , investigator 's judgment History clinically significant manifestation metabolic , hepatic , renal , hematologic , immunodeficiency , pulmonary , cardiovascular , gastrointestinal , urologic , neurologic , psychiatric disorder History anaphylaxis , hypersensitivity drug allergy , unless approve investigator sponsor History presence abnormal ECG , , investigator 's sponsor 's opinion , clinically significant ( include evidence previous acute myocardial infarction , complete leave bundle branch block , seconddegree heart block , complete heart block ) History significant alcohol abuse within 1 year prior screen regular use alcohol within 6 month prior screen visit History significant drug abuse within 1 year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen Current tobacco smoker ( positive history within 3 month initiation dose Day 1 ) , positive cotinine test checkin Positive drug screen screen checkin Positive pregnancy test result screen Day 1 breast feeding study Any serious medical condition abnormality clinical laboratory test , investigator 's judgment , preclude participant 's safe enrollment completion study Unwillingness comply condition , opinion investigator , would interfere ability comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>